ストックスクリーナーアプリを入手
5.78
3.67%
-0.22
アフターアワーズ：
6.12
0.34
+5.88%
Solid Biosciences Inc (SLDB) 最新ニュース
Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here? - MSN
Bain Capital life sciences invests $4.03 million in Solid Biosciences By Investing.com - Investing.com
Solid Biosciences sees $20.15m stock purchase by Perceptive Advisors - Investing.com
Research Analysts Issue Forecasts for SLDB FY2025 Earnings - MarketBeat
Wedbush Increases Earnings Estimates for Solid Biosciences - MarketBeat
Chardan Capital Forecasts Strong Price Appreciation for Solid Biosciences (NASDAQ:SLDB) Stock - Defense World
Solid Biosciences’ stock soars on early success in DMD gene therapy trial - MSN
Solid Biosciences (NASDAQ:SLDB) Given New $16.00 Price Target at Chardan Capital - MarketBeat
Solid Biosciences’ $200 Million Common Stock Offering - Global Legal Chronicle
Wall Street’s Top Picks: Solid Biosciences, Wingstop, and Diamondback Energy - PUNE.NEWS
Wedbush Adjusts Price Target on Solid Biosciences to $18 From $16, Keeps Outperform Rating - Marketscreener.com
Solid Biosciences surges on Duchenne therapy success - The Pharma Letter
Solid Biosciences shares gain on JMP Market Outperform rating By Investing.com - Investing.com South Africa
Solid Biosciences shares gain on JMP Market Outperform rating - Investing.com India
Solid Biosciences CFO Kevin Tan sells $12,529 in stock By Investing.com - Investing.com Nigeria
Solid Biosciences' Retail Following Swells Amid Stock's Best Run In A Year — What's Behind The Move? - MSN
Solid Biosciences' SWOT analysis: gene therapy stock poised for pivotal year - Investing.com Nigeria
Solid Biosciences Inc. (NASDAQ:SLDB) Receives $15.30 Average PT from Analysts - MarketBeat
Solid Biosciences Announces Pricing of Underwritten Offering - GlobeNewswire
Solid Biosciences CTO Herzich sells $10,644 in stock By Investing.com - Investing.com Australia
Solid Biosciences COO David Howton sells shares worth $22,021 By Investing.com - Investing.com Australia
Solid Biosciences chief regulatory officer sells shares for $12,192 By Investing.com - Investing.com South Africa
Solid Biosciences price target raised to $16 from $15 at Chardan - TipRanks
Solid Biosciences chief medical officer sells $12,893 in stock By Investing.com - Investing.com Canada
Solid Biosciences CEO Alexander Cumbo sells $45,005 in stock By Investing.com - Investing.com Australia
Solid Biosciences’ Gene Therapy SGT-003 Produces Microdystrophin Expression in Patients With DMD - CGTLive™
Solid Biosciences CFO Kevin Tan sells $12,529 in stock - Investing.com
Solid Biosciences CEO Alexander Cumbo sells $45,005 in stock - Investing.com
Solid Biosciences CTO Herzich sells $10,644 in stock - Investing.com
Solid Biosciences COO David Howton sells shares worth $22,021 - Investing.com India
Solid Biosciences Shares Up After Positive Results From Duchenne Drug Study, Prices $200 Million Offering - Marketscreener.com
Solid Biosciences stock soars on promising Duchenne therapy data - Investing.com India
Early DMD gene therapy data powers Solid Bio stock surge - FirstWord Pharma
Solid Biosciences Stock Surges On Upbeat Duchenne Muscular Dystrophy Gene Therapy Data - Benzinga
As part of turnaround, Solid Bio reports promising initial data for Duchenne gene therapy - Endpoints News
Solid says early data suggest ‘differentiated’ Duchenne gene therapy - BioPharma Dive
Solid Biosciences sets $200 million stock and warrant offering By Investing.com - Investing.com Nigeria
Solid Biosciences jumps on early-stage data from gene therapy - TradingView
Biotech Boom: Solid Biosciences (SLDB) Stock Skyrockets On Positive Developments - Stocks Telegraph
Morning Brew: Marjorie Taylor Greene's Stock Moves and Solid Biosciences' Surge - GuruFocus.com
Duchenne gene therapy from Solid Biosciences produces promising results in early study - STAT
Solid Bio stock rises on data for Duchenne drug (SLDB:NASDAQ) - Seeking Alpha
Solid soars as early DMD gene therapy data beat expectations - Fierce Biotech
Solid Biosciences sets $200 million stock and warrant offering - Investing.com India
Solid Biosciences Reports Positive Initial Clinical Data from SGT-003 -February 18, 2025 at 06:59 am EST - Marketscreener.com
Massive $200M Capital Raise: Elite Healthcare Investors Back Solid Biosciences Growth Plan - StockTitan
Solid Biosciences reports initial clinical data from INSPIRE DUCHENNE trial - TipRanks
Solid Biosciences Reports Promising Initial Data from Phase 1/2 INSPIRE DUCHENNE Trial for SGT-003 in Duchenne Muscular Dystrophy - Nasdaq
Solid Biosciences Reports Positive Initial Clinical Data - GlobeNewswire
Clinical Trial Breakthrough: Revolutionary Gene Therapy Achieves 110% Dystrophin in Duchenne Patients - StockTitan
Solid Biosciences Inc. (NASDAQ:SLDB) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):